TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38547895
Drug: Atezolizumab (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (800 mg intravenously every 2 weeks up to 1 year) plus modified docetaxel, cisplatin, and fluorouracil (mDCF) (eight cycles of 40 mg per m2 docetaxel, 75 mg per m2 cisplatin, and 750 mg per m2 fluorouracil)
Study: 38548365
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary ratings of emotional state and pain severity (children only) at baseline and post
Study: 38548367
Drug: Preadmission non-polypharmacy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preadmission non-polypharmacy (<5 medications)
Study: 38548367
Drug: Preadmission polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preadmission polypharmacy (5-10 medications)
Study: 38548367
Drug: Preadmission hyperpolypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preadmission hyperpolypharmacy (>10 medications)
Study: 38548367
Drug: Higher level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher level of medication use
Study: 38548404
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose azacitidine 50 mg/m plus venetoclax
Study: 38548404
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose azacitidine plus venetoclax
Study: 38550328
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine intervention delivery
Study: 38551394
Drug: TPST-1120 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPST-1120 monotherapy
Study: 38551394
Drug: TPST-1120 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPST-1120 in combination with nivolumab
Study: 38551501
Drug: CAR-GD2 T-cell
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-GD2 T-cell therapy
Study: 38551501
Drug: Tazemetostat (EZH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazemetostat (EZH2 inhibitor)
Study: 38551501
Drug: AP1903 (dimerizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 (dimerizing drug)
Study: 38551689
Drug: Potential drug-drug
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential drug-drug interactions (DDIs)
Study: 38551934
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment in TNS group (N = 14)
Study: 38551983
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral thiamine (600-1800 mg daily) for 4 weeks
Study: 38552188
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I), 7 weekly virtual sessions
Study: 38552197
Drug: Atezolizumab 1,200
Normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1,200 mg intravenously once every 3 weeks plus cabozantinib 40 mg orally once daily
Study: 38552315
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (SC-TCZ) treatment
Study: 38552653
Drug: Ad26.ZEBOV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
Study: 38552659
Drug: Standard-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose group (10 mg/kg once daily for 4 months)
Study: 38552659
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg group (20 mg/kg daily for 2 months)
Study: 38552659
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg group (30 mg/kg daily for 2 months)
Study: 38553062
Drug: Personalised prehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised prehabilitation programme including coached, supervised or self-directed physical activity and weekly dietary follow-up.
Study: 38553594
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (NCRT) followed by neoadjuvant consolidation chemotherapy (NCCT)
Study: 38554013
Drug: 10-week online
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week online fall prevention intervention (weekly virtual group discussions, individual phone check-ins, home exercises)
Study: 38554563
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV R-KET administration
Study: 38554717
Drug: sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab (200 mg on day 1) plus P-GEMOX (pegaspargase 2000 U/m2, gemcitabine, and oxaliplatin)
Study: 38554726
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of RGX-314 (dose range 3 × 10)
Study: 38554726
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of RGX-314
Study: 38554725
Drug: Afamitresgene autoleucel
Normalized name: Afamitresgene autoleucel
DrugBank: Afamitresgene autoleucel (DB18592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afamitresgene autoleucel (afami-cel), single intravenous dose (transduced dose range 1·0 × 10)
Study: 38555253
Drug: Plasma NPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma NPY levels above median (70 pg/ml)
Study: 38555253
Drug: Plasma NPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma NPY levels above median (70 pg/ml) after 4 months
Study: 38555285
Drug: CHK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHK1 inhibitor prexasertib (CHK1i) in cohort 5
Study: 38555285
Drug: CHK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHK1 inhibitor prexasertib (CHK1i) in cohort 6
Study: 38555336
Drug: Katz activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Katz activities of daily living (ADL) score
Study: 38555718
Drug: Cyclophosphamide (1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1.5-2 mg/kg/day orally for 6 weeks)
Study: 38555923
Drug: Anti-CD30 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD30 CAR T-cell infusion
Study: 38556413
Drug: Moderate hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug) administered 5 days a week for 4 weeks.
Study: 38556413
Drug: Moderate hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug).
Study: 38556640
Drug: Water Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Therapy
Study: 38557639
Drug: H56:IC31 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 (5 mg H56:500 nmol IC31)
Study: 38557692
Drug: Mobile WACh
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile WACh Empower intervention (tablet-based RH decision-support counseling tool and SMS support during two years of follow-up)
Study: 38557775
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (axi-cel; autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Study: 38557775
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transplantation in patients who had a response)
Study: 38558106
Drug: B-cell-targeted CAR
Normalized name: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
DrugBank: CTX120 (DB18625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-cell-targeted CAR T-cell therapy (tisagenlecleucel infusion)
Study: 38558387
Drug: Designed physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Designed physical therapy program (Control)
Study: 38559284
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of umbilical cord lining stem cells (ULSCs)
Study: 38559796
Drug: Single cDMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cDMARD plus anti-TNF therapy
Study: 38560407
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1a (sc IFN β-1a) 44 μg once weekly (qw)
Study: 38560556
Drug: Coronary atheroma
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary atheroma burden (AB), percent diameter stenosis (PDS), tapering reference diameter Z score (RDZ)
Study: 38560960
Drug: Low-dose amisulpride
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amisulpride (100-300 mg/day)
Study: 38560960
Drug: Olanzapine-fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine-fluoxetine combination (OFC) (5/10 mg + 20 mg)
Study: 38561497
Drug: Low-dose dengue
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dengue virus 3 (DENV-3) challenge
Study: 38561578
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) therapy withdrawal
Study: 38561815
Drug: 9-month all-oral
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-month all-oral short-course regimen containing bedaquiline (BDQ)
Study: 38561815
Drug: 9-month all-oral
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-month all-oral short-course regimen without bedaquiline (BDQ)
Study: 38970127
Drug: Posiphen 60
Normalized name: DOMIPHEN
DrugBank: Domiphen (DB11594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posiphen 60 mg once/day
Study: 38970127
Drug: Posiphen 60
Normalized name: DOMIPHEN
DrugBank: Domiphen (DB11594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posiphen 60 mg twice/day
Study: 38970127
Drug: Posiphen 60
Normalized name: DOMIPHEN
DrugBank: Domiphen (DB11594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posiphen 60 mg three times/day
Study: 38562833
Drug: MPER-peptide liposome
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPER-peptide liposome (500 mcg or 2000 mcg)
Study: 38562875
Drug: Transcutaneous auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS), administered twice daily during ICU stay.
Study: 38562875
Drug: Sham stimulation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation, administered twice daily during ICU stay.
Study: 38563246
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for NTM-PD
Study: 38563751
Drug: Albendazole in
Normalized name: Product containing albendazole in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole in combination with mebendazole
Study: 38563751
Drug: Albendazole in
Normalized name: Product containing albendazole in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole in combination with pyrantel
Study: 38563881
Drug: FDG-PET/CT before
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT before prednisolone treatment
Study: 38563881
Drug: FDG-PET/CT after
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT after 8 weeks of prednisolone treatment
Study: 38563881
Drug: FDG-PET/CT after
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET/CT after short-term prednisolone discontinuation at week 10
Study: 38564365
Drug: High-Dose Isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Isoniazid
Study: 38565086
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (25 μg every 2 h until Bishop score ≥7, labor, or maximum of 8 doses)
Study: 38565464
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine trial participation
Study: 38565814
Drug: Slow-release exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release exenatide (2 mg s.c. once a week)
Study: 38565886
Drug: XELOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX plus bevacizumab plus PD1-T cell immunotherapy
Study: 38565993
Drug: Plasma Kynurenine-to-Tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma Kynurenine-to-Tryptophan (K/T) ratio after successful TB treatment
Study: 38565993
Drug: Plasma Kynurenine-to-Tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma Kynurenine-to-Tryptophan (K/T) ratio upon treatment failure
Study: 38566164
Drug: NUC-3373 administered
Normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUC-3373 administered as monotherapy via intravenous infusion on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity.
Study: 38567031
Drug: Continuous prolonged
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous prolonged ECG recording using a patch ECG device (ECG247 Smart Heart Sensor)
Study: 38567081
Drug: 0 h hs-cTnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 h hs-cTnT <9 ng/L
Study: 38567081
Drug: 0 h hs-cTnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 h hs-cTnT <5 ng/L
Study: 38567081
Drug: 0 h hs-cTnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 h hs-cTnT <6 ng/L
Study: 38567196
Drug: Triple-drug antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug antiretroviral regimens (Control)
Study: 38568260
Drug: Atezolizumab in
Normalized name: atezolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab in combination with bosutinib
Study: 38568396
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg for 12 weeks
Study: 38568601
Drug: Facilitated telemedicine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facilitated telemedicine integrated into opioid treatment programs (n=290)
Study: 38568718
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with heat therapy in addition to standard care
Study: 38568956
Drug: Daily rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily rifapentine (600 mg) + isoniazid (300 mg) for 28 days
Study: 38568956
Drug: Twice-daily dolutegravir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dolutegravir (50 mg) during 1HP treatment
Study: 38569352
Drug: Perampanel (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (mean maximum dose, 3.5 mg/day for <4 years; 5.3 mg/day for 4-<12 years)
Study: 38569670
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality (VR) therapy as an add-on intervention
Study: 38569709
Drug: PVB+PCIA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB+PCIA (30 mL of 0.33% ropivacaine with dexamethasone)
Study: 38569709
Drug: ESPB+PCIA (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESPB+PCIA (40 mL of 0.25% ropivacaine with dexamethasone)
Study: 38569758
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with protocolized diuretic titration
Study: 38569774
Drug: Parenteral n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral n-3 polyunsaturated fatty acids supplementation (1.2 g/kg/d)
Study: 38569774
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (a mix of long-chain and medium-chain fats at 1.0 g/kg/d)
Study: 38569786
Drug: 4-week increase
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week increase in phenylalanine (Phe) intake (1500-3000 mg Phe/d)
Study: 38569788
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA (2.4 g daily from pregnancy week 24 until 1 week after birth)
Study: 38569821
Drug: Remote GDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote GDMT titration through the Medly heart failure program
Study: 38569821
Drug: Remote GDMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote GDMT titration
Study: 38570034
Drug: Cabozantinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib at 60 mg/day
Study: 38570034
Drug: Cabozantinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib as second-line treatment (n=27)
Study: 38570034
Drug: Prior therapies
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior therapies (one vs. two)
Study: 38570773
Drug: Helsana self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Helsana self-administered programme (n=81)
Study: 38570873
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisolone for 5 days
Study: 38570873
Drug: Low-dose colchicine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Study: 38573065
Drug: Model built
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model built with combination features of renal tumour, kidney, and PRAT.
Study: 38573466
Drug: Obesity-centric approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obesity-centric approach with anti-obesity medications
Study: 38573597
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose 51 to 60 Gy
Study: 38573597
Drug: Radiotherapy dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy dose 50 Gy or lower
Study: 38573597
Drug: Higher radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher radiotherapy dose (70 Gy as reference)
Study: 38573872
Drug: Infigratinib 125
Normalized name: INFIGRATINIB 125 mg ORAL CAPSULE [TRUSELTIQ]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infigratinib 125 mg by mouth once daily for 21 days (28-day cycle) for 2 cycles
Study: 38574312
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m) and Gemcitabine with Intensity-Modulated Radiation Therapy (IMRT)
Study: 38574757
Drug: Ticagrelor-based dual
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor-based dual antiplatelet therapy (DAPT) for 1 month
Study: 38574853
Drug: Interventional psychiatric
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional psychiatric treatments (INTs) including electroconvulsive therapy, transcranial magnetic stimulation, and esketamine
Study: 38574853
Drug: Interventional psychiatric
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional psychiatric treatments (INTs)
Study: 38575729
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52
Study: 38575854
Drug: Rapamycin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin (7 mg weekly for six months)
Study: 38575929
Drug: Multicomponent behavioral
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent behavioral intervention consisting of prescriber education via academic detailing, standardized patient post-extraction instructions, and blister packs of acetaminophen and ibuprofen.
Study: 38575945
Drug: JoyPop app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: JoyPop app (4 weeks, at least twice daily usage)
Study: 38576165
Drug: Conservative Approach
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Approach to Fluid Therapy
Study: 38576165
Drug: Liberal Approach
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal Approach to Fluid Therapy
Study: 38576178
Drug: BRV 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRV 200 mg/day
Study: 38577337
Drug: TYRP1-TCB (RO7293583)
Normalized name: TCB-008
DrugBank: TCB-008 (DB18352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYRP1-TCB (RO7293583) administered in escalating doses (0.045 to 0.4 mg)
Study: 38577574
Drug: Pasireotide 40
Normalized name: pasireotide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 40 mg/28 days intramuscularly for acromegaly or pasireotide 600 μg subcutaneously twice daily for Cushing's disease.
Study: 38577574
Drug: Incretin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incretin-based therapy or insulin (for those requiring additional/alternative antihyperglycemic medication).
Study: 38577574
Drug: Metformin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (for those who did not need antihyperglycemic medication).
Study: 38578158
Drug: High postoperative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High postoperative lactate (≥ 4 mmol/L)
Study: 38578667
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - Treatment as usual from the obesity unit.